Low-Cost Molecular Cervical Cancer Screening Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-11

Study Completion Date

2010-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Low-cost molecular human papillomavirus (HPV) testing may offer a more robust alternative to Pap smears and visual inspection for cervical cancer screening of underserved women. Two low-cost molecular tests for human HPV, the HPV E6 Test and the careHPV test, have been developed to detect cervical cancer by testing for HPV DNA. These tests take between 2 and 3 hours to run and may provide point-of-care (diagnostic testing at or near the site of patient care) testing for HPV. Researchers are interested in evaluating both tests to determine the best strategy for HPV testing of women who live in rural or underserved areas that have a high prevalence of cervical cancer diagnoses.

Objectives:

* To evaluate the clinical performance of the HPV E6 Test and careHPV in detecting cervical cancer and precancerous lesions.
* To evaluate the best low-cost test or combination of tests for women who have been referred for cervical cancer screening or treatment.
* To compare the clinical performance of self-collected specimens versus clinician-collected specimens in detecting cervical cancer and precancerous lesions.

Eligibility:

\- Women between 25 and 65 years of age who live in rural China.

Design:

* This study involves an initial testing visit and a 1-year followup visit for a high-risk subgroup.
* Participants will have the HPV E6 test, careHPV, and a visual inspection test for cervical cancer. For comparison, participants will also have the standard HPV test approved by the U.S. Food and Drug Administration.
* Participants who test positive for HPV on any of the above tests will also have colposcopy to collect samples of cervical tissue for further study.
* A random sample of women who test negative for HPV will also have colposcopy. Participants may also have biopsies if there is visual evidence of cervical abnormalities.
* At the 1-year followup visit, participants in the high-risk subgroup will have the same tests as in the previous visit..

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening

NCT02116920

CIN Cervix Cancer

UNKNOWN

Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer

NCT05531981

Uterine Cervical Neoplasms

UNKNOWN

Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia

NCT04274465

Cervix Lesion Cervical Cancer

COMPLETED

Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit

NCT04461678

Cervical Cancer

COMPLETED NA

Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood

NCT06082765

Cervical Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Low-cost, molecular human papillomavirus (HPV) testing may offer a more robust alternative to Pap smears and visual inspection with acetic acid (VIA) for cervical cancer screening of underserved women. Two low-cost molecular tests for human papillomavirus (HPV) have been developed: 1) AVantage HPV E6 Test (Arbor Vita Corporation, Sunnyvale, CA, USA) ( HPV E6 Test ) detects E6 oncoproteins from HPV16, 18, and 45 and 2) careHPV (Qiagen, Gaithersburg, MD, USA) detects the DNA for a pool of 14 carcinogenic HPV genotypes. The HPV E6 Test will be ready for the first clinical evaluations in 2010. The HPV E6 Test works like an ELISA in strip format such that it takes less than two hours to run and may provide point-of-care (diagnostic testing at or near the site of patient care) testing. careHPV, a batch HPV DNA test that takes 2.5 hours to perform, has already been developed and is currently being used in demonstration projects. The results to date for careHPV are promising. As our primary objective, we wish to evaluate both tests, and to evaluate the best low-cost triage strategies for careHPV-positive results in areas of high prevalence of carcinogenic HPV DNA. A study of 7,500 women, ages 25-65 years, identified from an age- and region-stratified sample of women living in rural China will be conducted. All women will be screened at enrollment, and a high-risk subgroup at the one-year follow-up, by the following tests: HPV E6 Test, careHPV, and visual inspection with acetic acid (VIA). Women will also be screened at enrollment, and a high-risk subgroup at the one-year follow-up, using the digene HC2 HPV DNA Test TM ( HC2 ) (formerly known as Hybrid Capture 2)(Qiagen), the first U.S. Food and Drug Administration-approved HPV test and the gold standard for clinical HPV testing. At both time points, all screen-positive women will be evaluated by colposcopy using a rigorous diagnostic protocol. A random sample of screen negatives will undergo colposcopy but will only undergo biopsies if there is visual evidence of cervical epithelial abnormalities. careHPV-positive specimens will be tested for most carcinogenic HPV genotypes, HPV16, HPV18, and HPV45 using careHPV16/18/45. This triage test utilizes the same test platform as careHPV but screens only for those 3 carcinogenic HPV genotypes. The primary goals are 1) to evaluate the clinical performance of careHPV, the HPV E6 Test, and VIA for detection of cervical precancer and cancer and 2) to determine the positive predictive values of VIA, the HPV E6 Test, and HPV16/18/45 detection by careHPV16/18/45 for cervical precancer and cancer among careHPV-positive women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DNA Probes E6 Protein Uterine Cervical Neoplasms HPV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. have not been previously diagnosed with cervical cancer
2. have a cervix
3. are not pregnant
4. are physically able to undergo routine cervical cancer screening 5) are able to provide informed consent
* We will not exclude women if they have had previous cervical cancer screening because we assume that even if a few women have been screened for cervical cancer, the quality of cytology screening was very poor.

Exclusion Criteria

1\) are not married AND report never having had sexual intercourse 2) have had a total hysterectomy

3\) have a history of cervical cancer

4\) are physically or mentally unable to undergo routine cervical cancer screening or unable to provide informed consent.

5\) are pregnant or have been pregnant in the last month

-Women who are currently menstruating at the time of enrollment will be deferred from participating, and will become eligible to participate 7-14 days after menstruation has ended. The menstruating women will be advised to return for the screening 7 to 14 days after their menstrual period has concluded.

Minimum Eligible Age

25 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes